CLEAN VERSION OF THE AMENDED CLAIM

1. A parvovirus vector having parvovirus DNA excisable from the vector DNA in a parvovirus-permissive cell, wherein the parvovirus DNA has a left terminus which comprises a parvovirus minimal origin of replication.

2. The parvovirus vector according to claim 1, wherein the left terminus of the parvovirus DNA comprises internal replication sequences.

3. The parvovirus vector according to claim 1 or 2, wherein the parvorisus minimal origin of replication comprises a consensus sequence of an NS1 nicking site.

4. The parvovirus vector according claim 1 or 2, wherein the parvovirus DNA originates from a mammalian parvovirus.

5. The parvovirus vector according to claim 1 or 2, wherein the parvovirus DNA is a rodent parvovirus.

6. The parvovirus vector according to claim 5, wherein the rodent parvovirus is MVM or H-1.

7. The parvovirus vector according to claim 1 or 2, wherein the parvovirus DNA comprises a combination of DNA sequences of various parvoviruses.

8. The parvovirus vector according to claim 7, wherein the parvovirus DNA originates from H-1 and the left terminus comprises a minimal parvovirus origin of replication of MVM.

9. The parvovirus vector according to claim 1 or 2, wherein the parvovirus DNA region coding for [the] capsid proteins is partially or fully replaced by an exogeneous DNA.

10. The parvovirus vector according to claim 9, wherein the exogenous DNA codes for a polypeptide usable in a treatment.

11. The parvovirus vector according to claim 10, wherein the polypeptide is a cytokine or a toxin.

12. The parvovirus vector according to claim 11, wherein the cytokine is a chemotactic polypeptide.

13. The parvovirus vector according to claim 12, wherein the chemotactic polypeptide is MCP-1.

14. The parvovirus vector according claim 1 or 2, wherein the parvovirus vector is present as a parvoviral particle.

15. A system comprising the parvovirus vector according claim 9 and a cell expressing the capsid proteins of parvovirus.

16. The system according to claim 15, wherein the expression of the capsid proteins is controlled by a helper plasmid comprising an SV40 origin of replication and the cell expresses an SV40 large T antigen.

17. The system according to claim 15, wherein the DNA coding for the capsid proteins is under the control of the parvovirus promoter P38.

18. A method of producing the parvoviral particle according to claim 14, comprising the steps of:

transfecting a parvovirus-permissive cell with the parvovirus vector according to claim 9,

expressing the capsid proteins of a parvovirus in the cell, and

isolating the parvoviral particle.

19. Use of the parvovirus vector according to claim 9 for gene therapy.

20. Use according to claim 19, wherein the gene therapy is carried out in the case of tumor diseases.

21. The parvovirus vector according to claim 3, wherein said consensus sequence of an NS1 nicking site is CTWWTCA.